Shu-Hui Liu
Chief Scientific Officer Multitude Therapeutics
Seminars
Wednesday 14th October 2026
From ADC Design Concept to Clinical Outcome: Contextualizing the Clinical Profile of Anti-MUC18 ADC AMT-253 in Melanoma
2:30 pm
- Breaking down the clinical profile to date of AMT-253 with durable response and manageable toxicity in Phase I late-line advanced melanoma clinical trial
- Recapping the translational journey of AMT-253 to highlight how design concept with T-Moiety exatecan platform leads to favorable clinical profile
- Highlighting AMT-253 clinical development strategy with first-in-class potential targeting MUC18 in melanoma
